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Background: Gabapentin (GBP) is known to suppress neuropathic hypersensitivity of primary afferents and the spinal
cord dorsal horn. However, its supra-spinal action sites are unclear. We identify the brain regions where GBP
changes the brain glucose metabolic rate at the effective dose that alleviates mechanical allodynia using
18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) scanning.
Results: Comparing the PET imaging data before and after the GBP treatment, the spared nerve injury-induced increases
of glucose metabolism in the thalamus and cerebellar vermis were reversed, and a significant decrease occurred in
glucose metabolism in the medial prefrontal cortex (mPFC), including the anterior cingulate cortex. GBP treatment also
reversed post-SNI connectivity increases between limbic cortices and thalamus.
Conclusions: Our results indicate that GBP analgesic effect may be mediated by reversing central hypersensitivity, and
suppressing mPFC, a crucial part of the cortical representation of pain, in the brain.
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Neuropathic pain results from damage or disease affecting
the somatosensory system [1]. The clinical features of
neuropathic pain include spontaneous pain, allodynia, and
hyperalgesia [2]. Gabapentin (GBP), a voltage-dependent
calcium channel α2δ subunit ligand, can effectively relieve
neuropathic pain caused by painful diabetic neuropathy,
postherpetic neuralgia, spinal cord injury, and phantom
limb pain [3-6]. Previous studies have indicated that the
analgesic effect of GBP acts primarily on the central ner-
vous system, particularly at the supraspinal level [7,8]. Re-
ports have indicated that GBP binds to various brain
regions [9,10]; however, which brain areas are involved in
the analgesic effect of GBP remains unclear.
Modern brain imaging techniques, such as functional
magnetic resonance imaging (fMRI) and positron emis-
sion tomography (PET), are crucial for studying pain
function [11-13], and can be used for screening effective
analgesics [14-17]. Blood oxygenation level-dependent* Correspondence: ctyen@ntu.edu.tw
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unless otherwise stated.(BOLD) MRI provides a higher resolution rodent brain
image; however, the changes of BOLD-MRI signals may
not reflect the analgesic effect because the rodents were
anesthetized. Instead, PET could provide the functional
brain imaging of behaving animals. Although rodents
must be anesthetized in the scanner for image acquisi-
tion, during the radiotracer uptake period, the rodents
could be kept awake and responsive to appropriate
stimulation [18-25]. For example, 18 F-fluorodeoxyglu-
cose (FDG), a glucose analog that serves as a functional
marker of glucose metabolism, requires 30 to 60 min for
radiotracer distribution and uptake through circulation
after injection into the tail vein of the rodent. During
this uptake time the rodents can be subjected to various
behavioral tests. Thus, FDG-PET could provide correl-
ation between behavior and glucose metabolism in the
rodent brain.
Recently, Kim et al. [26] and Thompson et al. [25] re-
ported that regional metabolic changes in the brain of rat
models of neuropathic pain could be revealed by the
FDG-PET scanning. But they focused on the persistent,
spontaneous pain after peripheral nerve injury. Allodynia,
a painful sensation induced by an innocuous stimulus, is. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Mechanical hypersensitivity after SNI and its reversal
by GBP treatment. (A) Mechanical allodynia was tested by von
Frey filaments. The 50% withdrawal threshold of the ipsilateral hind
paw of rats in the SNI group (n = 12) significantly decreased 3 d
after surgery, and remained lower for at least 14 d. The withdrawal
threshold of the contralateral hind paw of the SNI group and the
bilateral hind paws of the sham group (n = 10) showed no significant
changes after surgery. **indicates P < 0.01. Pre: pre-surgery. (B) Paw
withdrawal ratio of the 6 g von Frey filament stimulation before the
PET scan. In the SNI group (n = 12), the paw withdrawal ratio increased
significantly after SNI surgery, and decreased significantly after GBP
injection. The sham group (n = 10) showed no significant change in
the paw withdrawal ratio. **indicates P < 0.01. Naïve: pre-surgery;
SNI/Sham: post-surgery; GBP: post-surgery rats that received a
gabapentin injection.
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how mechanical allodynia affect the regional metabolic
activity in the rat brain. To realize which brain areas
would be altered under mechanical allodynia, and to re-
veal how the GBP exerts its analgesic effect in the brain,
we used FDG-PET to investigate the glucose metabolic
changes of the brain before and after GBP treatment
under the mechanical allodynia state of neuropathic rats.
We hypothesized that GBP works through the neuronal
activity of the brain to exert its analgesic effect, and glu-
cose metabolic changes could map such changes in neur-
onal activity.
Results
Mechanical allodynia developed after spared nerve injury
(SNI) of sciatic nerve
To verify whether the rats displayed mechanical allodynia
after SNI surgery, we assessed the paw withdrawal re-
sponses using the von Frey filaments test (Figure 1). In
the SNI group, the withdrawal threshold of the ipsilateral
hind paw decreased significantly at 3 d after surgery, and
maintained at least 14 d after surgery. The contralateral
hind paw showed no change in the withdrawal threshold
compared to its baseline. In the sham group, the with-
drawal threshold of both bilateral hind paws did not
change compared to their baseline. Thus the SNI rats
developed mechanical allodynia after surgery. These be-
havioral test results also indicated that SNI rats showed
consistency of behavioral hypersensitivity throughout the
experimental course of PET scans.
GBP alleviated mechanical allodynia
We tested whether GBP relieved mechanical allodynia in
the neuropathic rats. Figure 1B shows the behavioral re-
sults before PET scanning. According to mechanical
allodynia tests (Figure 1A), the normal (pre-surgery) paw
withdrawal thresholds of rats were between 18 and 25 g.
Thus we used the 6 g von Frey filament as an innocuous
tactile stimulus. In the SNI group, at the first PET scan
course, naïve rats that received a saline injection 60 min
before stimulation rarely showed paw withdrawal re-
sponses (baseline ratio: 2.4 ± 1.9%) in the stimulation
period. At the second PET scan course, the SNI-induced
neuropathic rats that received a saline injection showed
frequent paw withdrawal responses (17.6 ± 4.7%, P < 0.01
compared to the baseline ratio) in the stimulation
period. At the third PET scan course, after GBP injec-
tion, the paw withdrawal responses of neuropathic rats
decreased to the baseline level (1.4 ± 1.1%). GBP signifi-
cantly alleviated the paw withdrawal ratio (P < 0.01,
compared to the ratio of post-surgery stimulation) in the
SNI rats. Rats in the sham group did not show apparent
paw withdrawal behavior, and GBP given to these rats
did not alter this.Brain glucose metabolism mapping in response to GBP
treatment
To compare the changes of glucose metabolic activity in
the brain of neuropathic rats before and after GBP treat-
ment, each individual rat was scanned 3 times, first be-
fore and the second time 7 days after sciatic nerve
injury, and the third time after GBP treatment (Figure 2A
and B). FDG uptake values were normalized, and data
from different rats aligned according to bregma and an-
terior commissure (Figure 2C).
Figure 2 Experiment design and image co-registration landmarks. (A) Time course of the study. (B) The FDG-PET scans procedure. (C) Upper
row shows the bregma (arrow) in the CT images. The CT images scanned in the same session were used to align the PET images. Horizontal level
line was determined first as in the right panel, and the bregma was determined in the horizontal plan (left panel). PET and CT images were
resliced accordingly. Lower row shows resliced coronal images at the level of bregma. Note anterior commissure in the MRI image was used to
match the level of bregma.
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results. In the SNI group, comparing the SNI to the naïve
condition (Figure 3A), the glucose metabolism increased in
the bilateral anterior insular cortex (AIC, +2 mm),
thalamus (−3, −4 mm), and cerebellar (Cb) vermis
(−12, −13 mm), whereas it decreased in the contralateral
amygdala (AMY, −3 mm) and bilateral retrosplenial cor-
tex (RSC, −4 mm). Comparing the SNI rats that receivedthe GBP treatment to the SNI condition (Figure 3B), the
glucose metabolism decreased in the mPFC (+3 mm),
anterior cingulate cortex (ACC, +2, +3 mm), thalamus
(−3, −4 mm), and Cb vermis (−12, −13 mm), whereas it
increased in the bilateral upper lip regions of primary
somatosensory cortex (S1ULp, +2 to 0 mm) and ipsilat-
eral AG (−3 mm). In the sham group, comparison be-
tween before and after sham-surgery only showed slight
Figure 3 GBP action sites in the brain. Statistical t-map of PET images showed significant increases (warm color) and decreases (cold color) of
glucose uptake in the brains of SNI (upper rows) or sham (lower rows) rats between the first and second scan, (A) SNI vs. naïve and (C) Sham vs.
naïve, or the second and third scan, (B) GBP vs. SNI and (D) GBP vs. Sham. The PET scans are superimposed on the coronal sections of the brain.
L and R indicate the left (ipsilateral) and right (contralateral) brain, respectively. SNI group, n = 12; Sham group, n = 10. Abbreviations please refer
to the text.
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S1ULp (0 mm, Figure 3C). The sham group that received
GBP injection (Figure 3D) showed slight decrease of glu-
cose metabolism in the basal ganglia (0 mm), and in-
creased relative small area in the ipsilateral S1ULp
(0 mm).
Region of interest (ROI) analysis verified the SPM maps
To verify the SPM results, we quantified the relative ac-
tivity changes of specific brain structures as activation
index (AI) values. Table 1 shows the results of the ROIs
analysis. In the SNI group, comparing the SNI to the
naïve condition, the AI increased significantly in the
bilateral IC, the ipsilateral posterior thalamic nuclei (Po)
and ventral posterior thalamic nuclei (VP), and Cb
vermis, whereas it decreased significantly in the contra-
lateral AMY and bilateral RSC. Comparing the GBP to
the SNI condition, the AI decreased significantly in the
bilateral mPFC, the ipsilateral ACC, the bilateral Po, the
contralateral VP, and the Cb vermis, whereas it increased
significantly in the bilateral S1ULp, barrel field region of
S1 (S1BF) and secondary somatosensory cortex (S2), and
the ipsilateral AMY. Although the SPM maps displayed
slight changes of glucose metabolism, the sham group
showed no significant changes of AI in the cortex, thal-
amus, and cerebellum compared to the naïve condition
or the sham rats that received a GBP injection. According
to the ROI analysis, these results were consistent with
the SPM imaging maps.
Functional connectivity of the brain regions in different
conditions
To reveal the correlations of glucose metabolism among
distinct brain regions in different conditions, we classifiedsix functional groups and displayed the cross-correlation
matrices showing the functional connectivity of SNI rats
(Figure 4). Before SNI surgery (the naïve state), the dis-
tinct brain regions showed sparse correlation. After SNI
surgery, apparent correlations were represented among
various brain regions. There were 3 main clusters ap-
peared in the interregional correlation matrix, including
basal ganglia to limbic cortex, basal ganglia to thalamus,
and thalamus to limbic cortex. The basal ganglia showed
more connectivity with thalamus and limbic cortex after
SNI surgery, especially in the bilateral caudate-putamen
(CPu, Figure 4B,C). We further focused in particular on
the functional connectivity between thalamus and limbic
cortex (Figure 4D). The selected ROIs of thalamus
included bilateral VP, Po, MD, and submedius thalamic
nucleus (Sub). The selected ROIs of limbic cortex
included bilateral mPFC, ACC, lateral orbital cortex (LO),
and ventral orbital cortex (VO). After SNI surgery, the
mPFC showed more connectivity with selected thalamic
nuclei except ipsilateral VP and Sub. The VO showed well
connectivity with thalamus except bilateral VP and ipsilat-
eral Sub. The ACC showed less connectivity with bilateral
Po and contralateral Sub. The SNI-induced correlations
were nearly reversed after GBP treatment. In general, the
two functional groups displayed notable correlation after
SNI surgery, and GBP disputed this connectivity.
Discussion
By serial longitudinal FDG-PET scanning of the same rat
before, during neuropathic states and immediately follow-
ing GBP treatment, we obtained 3 major findings in the
present study. (1) Glucose metabolism increased in the
bilateral IC, thalamus, and Cb vermis, and decreased in
the AMY and bilateral RSC in SNI rats under mechanical
Table 1 Activation index (%) by region of interest (ROI) analysis in different conditions of SNI and sham groups
ROIs SNI group (n = 12) Sham group (n = 10)
Naïve SNI GBP Naïve Sham GBP
mPFC i 36.5 ± 2.1 35.2 ± 2.0 * 29.6 ± 1.1 34.6 ± 2.2 35.9 ± 1.3 31.5 ± 1.6
mPFC c 37.9 ± 1.8 35.0 ± 2.0 * 29.7 ± 1.2 33.1 ± 2.2 33.5 ± 1.5 28.6 ± 2.0
ACC i 36.9 ± 1.7 37.4 ± 2.6 * 31.4 ± 1.3 37.3 ± 1.8 37.9 ± 1.5 34.1 ± 2.8
ACC c 34.7 ± 1.4 35.6 ± 2.6 32.3 ± 1.4 34.5 ± 1.8 35.8 ± 1.9 32.2 ± 2.8
RSC i 20.0 ± 1.7 # 14.8 ± 2.4 14.5 ± 2.1 18.9 ± 1.7 15.1 ± 2.3 15.4 ± 2.4
RSC c 20.2 ± 1.6 # 14.8 ± 2.3 13.7 ± 2.2 18.8 ± 1.9 15.0 ± 2.8 15.0 ± 2.8
IC i 1.4 ± 1.5 # 4.8 ± 1.4 3.6 ± 1.8 1.3 ± 2.1 0.3 ± 2.1 1.6 ± 3.1
IC c 1.3 ± 1.4 # 5.1 ± 1.5 3.6 ± 1.6 1.4 ± 2.0 0.5 ± 2.1 1.5 ± 3.0
S1HL i 14.7 ± 1.3 15.7 ± 1.3 15.1 ± 2.0 15.3 ± 1.6 12.3 ± 1.5 13.0 ± 3.1
S1HL c 15.3 ± 1.6 15.7 ± 1.6 15.2 ± 1.1 13.5 ± 2.3 12.5 ± 1.6 13.0 ± 3.0
S1BF i 18.7 ± 0.9 18.0 ± 1.6 ** 25.0 ± 1.0 18.5 ± 1.3 18.5 ± 1.1 21.5 ± 2.4
S1BF c 18.6 ± 1.0 18.7 ± 1.5 ** 25.7 ± 1.0 18.5 ± 1.3 17.6 ± 0.8 22.6 ± 2.4
S1ULp i 19.4 ± 1.6 19.7 ± 1.5 *** 27.2 ± 1.2 21.8 ± 1.3 22.6 ± 1.8 25.9 ± 2.0
S1ULp c 17.9 ± 1.5 19.3 ± 1.6 ** 27.1 ± 1.4 22.3 ± 2.0 21.1 ± 0.9 24.0 ± 2.2
S2 9.8 ± 1.9 10.4 ± 1.7 * 16.4 ± 1.9 11.9 ± 1.4 10.4 ± 1.8 15.2 ± 2.0
S2 10.4 ± 2.2 10.8 ± 1.8 ** 20.1 ± 1.4 14.3 ± 1.7 10.8 ± 1.3 13.6 ± 2.1
M1 i 14.1 ± 2.3 15.2 ± 1.5 15.5 ± 0.8 16.2 ± 1.8 15.3 ± 2.0 16.7 ± 3.1
M1 c 13.9 ± 2.9 13.3 ± 1.8 16.1 ± 1.1 14.6 ± 1.7 15.3 ± 2.1 15.2 ± 2.8
CPu i 31.8 ± 1.6 28.6 ± 1.9 28.6 ± 1.3 28.6 ± 1.5 28.9 ± 1.4 28.7 ± 2.2
CPu c 33.7 ± 1.2 28.8 ± 1.9 29.7 ± 1.4 30.4 ± 1.4 28.9 ± 1.5 29.5 ± 2.2
Po i 21.4 ± 1.1 # 26.2 ± 1.6 ** 21.0 ± 1.3 22.2 ± 1.2 23.9 ± 1.2 21.8 ± 2.3
Po c 24.5 ± 1.0 27.8 ± 1.7 ** 22.3 ± 1.4 23.7 ± 1.2 25.0 ± 1.4 23.3 ± 2.1
VP i 8.4 ± 1.1 ## 13.2 ± 1.2 9.5 ± 1.1 11.1 ± 1.3 10.0 ± 1.2 8.2 ± 1.8
VP c 9.3 ± 1.0 12.3 ± 0.9 * 9.2 ± 1.1 10.1 ± 1.3 11.0 ± 1.2 8.5 ± 1.7
AMY i -9.3 ± 1.2 -11.3 ± 1.3 * -7.9 ± 1.2 -10.9 ± 0.9 -13.0 ± 1.4 -10.4 ± 0.9
AMY c -5.3 ± 1.2 # -7.0 ± 1.1 -5.8 ± 1.4 -8.1 ± 0.6 -10.0 ± 1.3 -9.3 ± 1.0
Cb vermis 4.7 ± 1.7 ## 12.0 ± 1.2 ** 6.9 ± 1.2 5.2 ± 1.7 5.6 ± 1.7 7.2 ± 2.0
Post-surgery (SNI) compared to pre-surgery (Naïve) by the one-way repeated measures ANOVA, #P < 0.05, ##P < 0.01. Gabapentin treatment (GBP) compared to
post-surgery by the one-way repeated measures ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001. i: ipsilateral; c: contralateral. Data were presented as mean ± SEM.
Abbreviations refer to the main text.
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function of thalamus, AMY and Cb vermis in the SNI
rats, and suppressed the glucose metabolism in the
mPFC. And (3) functional connectivity between thalamus
and limbic cortical structures increased in SNI rats. This
increase was alleviated by GBP treatment. Although
GBP-induced pharmacological effects in the rat brain
have been revealed by pharmaco-MRI (phMRI) or fMRI
[14-16,27] studies, to our knowledge, this study is the
first PET report to demonstrate the action of GBP in the
brain of neuropathic rats.
Allodynia is a major symptom in neuropathic pain pa-
tients, and its brain mechanism remains an open issue.
Several studies focused on the functional abnormalities
in the brain of allodynic state of the patients with neuro-
pathic pain [28-32]. Brain areas including S1, secondarysomatosensory cortex (S2), ACC, IC, mPFC, and thal-
amus [11,33] have been found changed activity. Because
the difficulty in patient recruitment, different etiology
and disease history might alter the brain areas in these
studies. It is also ethically difficult to follow the same hu-
man patient longitudinally before and during the devel-
opment of neuropathic pain. In the present study, we
used animal model as a surrogate to probe the functional
changes in the brain of SNI rats. We performed an in-
nocuous mechanical stimulation during the FDG uptake
period while the rats were awake in the testing apparatus.
The behavioral results indicated that rats after SNI sur-
gery exhibited frequent paw withdrawal behavior, which
suggested the neuropathic rats might experience tactile
allodynia. In our observations, the neuropathic rats in re-
sponse to the light tactile stimulation not only withdrew
Figure 4 Functional connectivity in the brain of pre-SNI, post-SNI and GBP-treated conditions. (A) Interregional correlation matrices of the
3 conditions of SNI rats. Pearson’s correlation coefficients were color-coded. The warm and cold color scales stand for positive and negative
significant correlations, respectively. Note the strong positive connections were appeared in the (B) basal ganglia to limbic cortex, (C) basal
ganglia to thalamus, and (D) thalamus to limbic cortex. The enlarged rectangles in (B) to (D) represent the detail of correlation matrices boxed in
A. SNI rats, n = 12.
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or licking of the paw, suggesting these behaviors were
not merely the simple reflex to the stimulation. When
GBP was injected to the neuropathic rats, these abnormal
behaviors were alleviated significantly.
Recently, Kim et al. [26] and Thompson et al. [25] re-
ported the changes of glucose metabolic activities in the
brain of neuropathic rats under the resting state. The al-
terations they observed could implicate the functional
adaptation of spontaneous pain in the rat brain. In the
present study, the PET scan results which compared the
changes of glucose metabolic activities before and after
SNI surgery revealed that IC, thalamus, and Cb vermis
showed hyper-activation, whereas AMY and RSC showed
hypo-activation. These metabolic activity changes might
be the signatures of the mechanical allodynia in the rat
brain. In the cortical level, anterior IC plays a major role
in the cortical representation of pain and is part of the
affective-motivational components of pain [34]. IC is
considered as an integration region of sensory and emo-
tional inputs. Several PET studies showed IC activation
of neural activity in the allodynia state [29,32,35]. Our
results suggested that bilateral IC activation related tothe allodynia state of neuropathic rats. The RSC showed
decreased glucose metabolism in the neuropathic rats.
Although the functions of RSC in nociception processing
remain to be elucidated, it was suggested the alteration of
RSC might be relate to change of default mode network
[36,37].
In the subcortical level, the activation of the thalamus
might relate to the nociceptive response. Previous studies
indicated that damage to the somatosensory system
caused higher neuronal activity [38,39] and glucose
utilization [40] in the thalamus. The ROI analysis further
revealed significant activation in the ipsilateral PO and
VP, but not in the contralateral side. Iadarola et al. [41]
reported that patients with chronic neuropathic pain dis-
played deactivation of contralateral thalamic activity
under PET scanning. It was expected that painful stimuli
would induce activation of thalamic activity in the
contralateral side. According to the ROI analysis, after
spared nerve injury, the bilateral thalamus (including Po
and VP) showed increased glucose metabolism. There
was no statistical significance between the ipsilateral and
contralateral thalamus. The AMY showed deactivation in
our study. The AMY is involved in several aspects of
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Several functional imaging studies have reported the de-
creased activity in AMY during painful stimulation
[28,43,44]. Although our results indicated that contralat-
eral AMY showed significant deactivation, according to
ROI analysis (Table 1), there was a trend that bilateral
AMY decreased glucose metabolism under allodynic
state. In addition to the forebrain, the activation of the
cerebellum was also observed. The activation of the cere-
bellum during allodynic stimulation might not only relate
to paw withdrawal behavior, but play a role in sensory
processing [45].
One might argue that there was no activation in the
contralateral hindlimb region of S1 (S1HL) in our study.
Neither SPM results nor ROI analysis showed elevated
glucose metabolic activity in the bilateral S1HL. SI activa-
tion was not found in a recent FDG-PET study of the
spinal nerve ligated rat [26]. The activation of S1 in the
neuropathic pain patients is also controversial [46]. Sev-
eral studies reported that brush-evoked allodynia in
neuropathic patients increased regional cerebral blood
flow (rCBF) or BOLD signals in the S1 [28-30]. However,
using similar experimental design to detect rCBF in the
neuropathic patients during brush-evoked allodynia, Wit-
ting et al. [32] reported that there were no significant
changes in the thalamus, S1, and ACC. The absence of
S1 activity might be the pathophysiological consequence
of the animal model we used. Even though our results in-
dicated that thalamus showed robust activation after allo-
dynic stimulation. Seminowicz et al. [47] reported that
after spinal cord injury, rats displayed functional discon-
nection between thalamus and S1. This finding provided
another possible mechanism for the absence of S1 activ-
ity. We also performed functional connectivity analysis.
Our data indicated that activation in the thalamus had
higher correlation with limbic cortex but not with som-
atosensory cortex in the SNI rats.
After receiving GBP treatment, several brain regions
reversed their metabolic activity patterns back to their
baseline levels before nerve injury. The most prominent
changes were present in the thalamus, AMY and Cb ver-
mis. The thalamus showed activation under the allodynia
state, and after GBP treatment, the increased glucose me-
tabolism reverted to the baseline level (Table 1). The
reversion of thalamic activity by GBP treatment was simi-
lar to Takemura et al. [27], though our methodology was
different. The ROI analysis indicated a significant de-
crease in the bilateral PO and contralateral VP, which
might reflect the analgesic effect of GBP. Deactivation
also presented in the cerebellum. Because the paw with-
drawal ratio reduced substantially, the decreased glucose
metabolism might reflect reduced neural activity. Hooker
et al. [15] demonstrated that the cerebellum showed
activation of BOLD signals after GBP infusion. Thisdiscrepancy might be due to that their animals were
anesthetized, whereas our animals were awake. Activa-
tion of the AMY might be another manifestation of re-
versed neural activity induced by GBP treatment.
Besides, the mPFC and ACC showed specific deactiva-
tion after GBP treatment. The function of mPFC is re-
lated to affect, emotion, memory and decision making
[34]. Millecamps et al. [48] reported that directly injected
a partial agonist of NMDA receptor into mPFC could in-
duce antinociception in SNI rats, but not into thalamus
or IC. Jiang et al. [49] described that antinociception by
motor cortex stimulation would suppresses the BOLD
signals in the mPFC. These studies suggested that mPFC
play an important role in regulating pain processing in
the brain. The ACC is one of the main cortical structures
in regulating the affective and emotional component of
pain [34]. Takemura et al. [27] described that after GBP
injection, the increased BOLD signals of neuropathic rats
would revert to baseline. Recent studies indicated that
after nerve injury, the glutamate transmission augmented
in the ACC [50-53]. Bak et al. [54,55] demonstrated that
glucose utilization is correlated with glutamatergic cell
activity. Although mPFC and ACC did not change their
glucose metabolism under the allodynic stimulation, after
GBP treatment, the mPFC and ACC showed significant
deactivation. This deactivation of neural activity is similar
to GBP-induced pharmacodynamic effects in the neuro-
pathic rats [15]. The sham group animals which received
the same dosage of GBP injection did not alter the
glucose metabolism in the mPFC and ACC. These
neuropathic-specific GBP changes might relate to the an-
algesic effect of the drug. The S1ULp, S1BF and S2
showed strong activation after GBP treatment in the
neuropathic rats. The glucose metabolism of the sham
group showed a trend of increase in the S1ULp, S1BF
and S2 after GBP treatment, although the changes did
not reach statistical significance. Though we did not
realize the mechanism of such finding, the relative high
glucose metabolism of the S1ULp, S1BF and S2 might be
a specific effect of the GBP treatment in the neuropathic
rats.
This study included several limitations. First, FDG-PET
cannot discriminate excitatory from inhibitory neural
activity, because both neural activities consume energy
and increase the glucose metabolic rate. Deactivation of
neural activity might reflect reduced neural activity; how-
ever, it cannot differentiate whether the deactivation is
caused by the suppressed glutamatergic cells or the
inhibitory outcome of activation of GABAergic cells.
Further electrophysiological experiments are needed to
investigate whether the metabolic activity changes are
neuronal. Second, our acquired PET images were static
and cumulative signal counts of the total FDG uptake
period, and thus contained no dynamic information.
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changes of glucose metabolism in the brain might not be
the direct effect of the drug. It cannot separate the spinal
or supraspinal mechanisms of the drug effect, the func-
tional brain changes only represent the total analgesic ef-
fect of the drug. Nevertheless, because of numerous
binding sites of GBP [9,10] and the preferential action
[7,8] in the brain, our finding might implicate the prob-
able areas that involved in the analgesic effects of GBP.Conclusions
GBP is the first-line analgesic in relieving neuropathic
pain. We used longitudinal FDG-PET to measure the
change in brain metabolic activity during the analgesic
action of GBP in awake neuropathic rats. Our findings
suggest that mPFC, ACC, thalamus, and cerebellum
might be the primary sites of analgesic action of GBP.
By means of FDG-PET scan, we could recognize the ac-
tion sites of analgesics in the brain of awake animals,
and this methodology can serve as a promising tool for
understand the effect of the analgesic drugs.Methods
Animals
We used 22 male Sprague–Dawley rats in this study.
Six-week-old rats (weighing from 180 to 210 g) were
purchased from BioLasco Company in Taiwan. Groups
of 2 to 3 rats were housed together in plastic cages and
were placed in a temperature- and humidity-controlled
room (23 ± 2 °C and 55 ± 5%) with a 12-h light/dark
cycle (lights on at 06:00 h). Food and water were avail-
able ad libitum. All animal care and experimental proce-
dures were approved by the Institutional Animal Care
and Use Committee of National Taiwan University. The
guidelines established by the Codes for Experimental
Use of Animals from the Council of Agriculture of
Taiwan, based on the Animal Protection Law of Taiwan,
were adhered to.Surgery
We used the SNI model for neuropathic pain. The ex-
perimental surgery procedure was in accordance with
Decosterd and Woolf [56]. Under sodium pentobarbital
(50 mg/kg, i.p.) anesthesia, we exposed the sciatic nerve
of the left leg and its trifurcate branches. We tightly li-
gated the common peroneal and tibial nerves with 6.0
silk and cut distally to the ligation site, leaving the sural
nerve intact. After surgery, we closed the muscle and
skin in 2 layers. For sham surgery, we exposed the sciatic
nerve and its branches. The wound was closed in 2
layers without additional operation of the sciatic nerve
branches.Drug and treatment regimen
GBP powder (purity 98%) was purchased from Tokyo
Chemical Industry Co., Ltd., Japan. GBP powder was dis-
solved in 0.9% saline and freshly prepared for each ex-
periment. We obtained the GBP dosage (100 mg/kg)
used in this study from previous studies [57-59], and
validated the efficacy of this dosage of GBP with pre-
liminary tests. A bolus of GBP solution was injected
intraperitoneally 60 min prior to behavioral stimula-
tion for the drug to reach its maximum analgesic ef-
fect (Figure 2B) [58].
Behavioral tests
To confirm whether the rats developed neuropathic pain
after surgery, we assessed the mechanical allodynia using
the von Frey filaments (North Coast Medical, Inc.,
Morgan Hill, USA) test. Each rat was individually placed
on an elevated wire mesh floor in the transparent acrylic
box (dimensions 21 cm× 12 cm× 14 cm) and allowed to
acclimate for 10 min. We applied the von Frey filaments
of various bending forces (0.6, 1, 2, 4, 6, 8, 15, and 26 g)
to the lateral plantar surface, innervated by the sural
nerve of the hind paw, to test the withdrawal response.
The behavioral test procedure was in accordance with
Chaplan et al. [60]. Brisk withdrawal or paw flinching
was regarded as positive response. At the beginning, the
2 g von Frey filament was applied to the hindpaw, the
next stronger or weaker filaments were applied accord-
ing to the prior response (positive or negative). The re-
sponse patterns and 50% withdrawal threshold were
calculated based on Chaplan et al. [60]. To prevent the
influence of the behavioral test from the mechanical
stimulation of the PET scan course, we assessed the tact-
ile withdrawal thresholds on the following days: 2 d be-
fore surgery as the baseline, and 3, 5, 8, and 14 d after
surgery (Figure 2A).
FDG-PET scan protocol
The time course of FDG-PET scans and scanning pro-
cedure are shown in the Figure 2A. The rats were ran-
domly divided into SNI (n = 12) and sham (n = 10)
groups. Each rat underwent the PET scan 3 times. The
first scan (naïve control) was performed 1 d before sur-
gery, the second scan (neuropathic/sham) 7 d, and the
third scan (neuropathic/sham with gabapentin treat-
ment) 10 d after surgery.
The rats were fasted overnight before each scan to en-
hance FDG utilization during the PET experiment. For
PET study, each rat received 2–2.5 mCi of FDG by tail
vein injection with the aid of brief (less than 2 min) iso-
flurane inhalation (5% in 100% oxygen). After FDG in-
jection, the rat was placed immediately into a
transparent acrylic box, which was constituted with wire
mesh floor for von Frey filament to pass through. The
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scanning. During the FDG uptake period, the first 10 mi-
nutes were allowed for the rat to recover from anesthesia.
We used a 6 g von Frey filament to stimulate the lateral
plantar surface of the left (nerve-injured) hind paw of the
rat from 10 to 30 min after FDG injection. The left hind
paw received mechanical stimulation once every 5 s
during the 20 min stimulation period (a total of 240 stim-
ulations). The duration of each stimulus was 1 s. We
counted the paw withdrawal times and transformed the re-
sults as the withdrawal ratio (in percentage). After mech-
anical stimulation, each rat was allowed to rest for another
10 min. At the end of the 40 min FDG uptake period, the
rat was anesthetized by isoflurane inhalation (5% in 100%
oxygen). After reaching a deep state of anesthesia, the rat
was placed into the PET scanner with the head holder (to
prevent motion artifact) and continuously maintained with
isoflurane inhalation (2% in 100% oxygen) until the end of
the scan. The scan time was 40 min for PET and 7 min for
computed tomography (CT).
The FDG uptake in the brain was measured using an
eXplore Vista Dual-Ring Small-Animal PET/CT scanner
(GE Healthcare, Waukesha, WI) with an average full
width at half maximum (FWHM) resolution of 1.26 mm.
The images were first anatomically standardized to
achieve symmetrical midline alignment. To improve the
resolution and sensitivity of acquired images, the images
were reconstructed by the 3D ordered subsets expect-
ation maximization (OSEM) algorithm. The nominal
voxel size was 0.387 mm × 0.387 mm × 0.775 mm. Each
of the 61 transverse slices in the reconstructed images
contained 175 × 175 voxels. FDG uptake by brain regions
was quantified as standardized uptake values (SUVs)
using the formula:
SUV ¼ regional FDG concentration Bq=mlð Þ
= injected FDG dose Bqð Þ  body weight kgð Þ:
PET images processing
We performed the PET images processing according to
our previously published voxel-based SPM analytical
method [21]. Briefly, we used the software Medical
Image Processing, Analysis and Visualization (MIPAV, ver-
sion 4.1.2, Center for Information Technology, National
Institutes of Health, USA) and SPM (SPM8, Wellcome
Trust Centre for Neuroimaging, Institute of Neurology,
UCL, United Kingdom) to do the image preprocessing
and to generate the statistical parametric maps. For image
preprocessing: (1) To facilitate images re-alignment, we
rotated and translated each brain images (PET/CT/MRI)
to a standard space, and adjusted the resolutions to
the same attributes by MIPAV. The corresponding,
size-matched MRI images were obtained from our lab’sMRI database, which served as anatomical images. The
slice of bregma in CT images and the slice of anterior
commissure in MRI images were chosen as indices of the
coordinate origin to align these 2 sets of images. Because
eXplore Vista PET/CT scanner provided the same coor-
dinates of the PET and CT images, then PET images
could be aligned with the MRI images (Figure 2C). (2)
The raw PET images were first coregistered to their cor-
responding, size-matched T2-weighted MRI images.
(3) For each PET image, the signals outside the brain
were cropped with a brain mask; the brain mask was
drawn manually from their corresponding, size-matched
MRI image using MIPAV. (4) The cropped PET images
were further coregistered, spatial normalized, and resliced
to a template T2-weighted MRI image (coordinate
corrected) [61], and the final voxel size of the prepro-
cessed PET images was 0.2 mm × 0.2 mm× 0.2 mm.
The statistical parametric maps were generated using the
voxel-wise paired t test and 2-sample t test for intra-
subject and inter-subject comparison, respectively.
Global normalization scaling was applied. Significant
clusters were determined according to an individual
voxel threshold of P < 0.05 with at least 30 continuous
voxels.
ROI analysis
To verify the accuracy and consistency of results repre-
sented by SPM, we further investigate the relative activ-
ities of specific brain structures, which showed
significant changes of glucose metabolism among differ-
ent conditions, by ROI analysis. The specific brain struc-
tures included mPFC, ACC, RSC, IC, S1HL, S1ULp,
S1BF, S2, primary motor cortex (M1), CPu, Po, VP, AMY,
and Cb vermis. All bilateral structures except Cb vermis
were separately analyzed. We used OsiriX Imaging soft-
ware (Pixmeo, Geneva, Switzerland) to extract the SUVs
of selected ROIs. We merged the PET images with the
corresponding, size-matched MRI images by means of
CT coordinates. All the ROIs were delineated with the
aid of corresponding MRI images according to the atlas
of the rat brain [62]. To quantify the individual ROI
activity as a percentage difference of average total activity
of the entire brain, we calculated the AI [63] as the
formula:
AI ¼ Sampled ROI SUVs‐Average total brain SUVsð Þ
= Average total brain SUVs 100%
Connectivity analysis
To determine whether the correlations of glucose metab-
olism among distinct brain regions were altered before
SNI, after SNI and after GBP treatment, we performed
the functional connectivity analysis. Cross-correlation
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variability of brain FDG consumption. The ROIs of brain
areas were defined according to the atlas of the rat brain
[62]. The selected ROIs divided into six functional groups
(Figure 4A): sensorimotor area, basal ganglia, AMY/
hippocampus (Hipp), limbic cortex, thalamus and peria-
queductal gray (PAG). The sensorimotor area group in-
cludes Cb vermis, left M1, right M1, left secondary
motor cortex (M2), right M2, left forelimb region of S1
(S1FL), right S1FL, left S1HL, right S1HL, left S2, and
right S2, respectively. The basal ganglia group includes
left CPu, right CPu, left nucleus accumbens (NAc), right
NAc, left ventral pallidum, and right ventral pallidum, re-
spectively. The AMY/Hipp group includes left basolateral
AMY (BLA), right BLA, left central nucleus of AMY
(CeA), right CeA, left Hipp, and right Hipp, respectively.
The limbic cortex groups include left mPFC, right mPFC,
left lateral orbital cortex (LO), right LO, left ventral
orbital cortex (VO), right VO, left ACC, right ACC, left
middle cingulate cortex (MCC), right MCC, left RSC,
right RSC, left posterior IC (PIC), right PIC, left AIC, and
right AIC, respectively. The thalamus group includes left
VP, right VP, left Po, right Po, left mediodorsal thalamic
nucleus (MD), right MD, left Sub, and right Sub, respect-
ively. The PAG group includes dorsal PAG, left ventral
lateral PAG (vlPAG), right vlPAG, left lateral PAG
(lPAG), and right lPAG, respectively. ROI masks were
drawn on the template brain image for all PET data
which to be coregistered. These ROI masks were used to
extract the AI values from each PET brain image.
The paired brain areas with significantly correlated
inter-subject variability of brain FDG consumption (P <
0.05, false discovery rate (FDR) corrected) were shown in
the matrix with warm and cold color mapping for posi-
tive and negative correlation, respectively, and the non-
significances were colored with black. For example, if the
column x, row y of a matrix refer to the brain areas of A
V.S. B, which were significantly and positively correlated
in their FDG consumption, it would be marked with
warm color, and the brightness of the color refers to the
corresponding Pearson’s correlation coefficient r value
shown in the color bar.
Data analysis
We conducted the statistical analysis using SigmaStat (ver-
sion 3.11) and presented the results as mean ± SD. Data
were considered statistically significant at P < 0.05. For the
behavioral test, we evaluated the differences in withdrawal
thresholds using one-way repeated measures ANOVA and
Tukey’s post hoc multiple comparison. For mechanical
stimulation before FDG-PET scanning, we evaluated the
differences in withdrawal ratio among various conditions
using one-way repeated measures ANOVA and Tukey’s
post hoc multiple comparison. For PET image analysis, weused SPM8 to conduct voxel-based analysis of PET im-
ages based on a paired t-test comparison. We considered
P < 0.05 (uncorrected) to be statistically significant. T-
value maps of the results were superimposed on coronal
views of a representative MRI images to define voxels,
showing significant changes. For ROI analysis, we evalu-
ated the differences in the AI among various conditions
using one-way repeated measures ANOVA and Tukey’s
post hoc multiple comparison.
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